{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:45:12Z","timestamp":1787499912075,"version":"build-2736575974"},"reference-count":11,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2017,2]]},"abstract":"\n Background:<\/jats:title>\n Fingolimod is an oral disease-modifying therapy for relapsing forms of multiple sclerosis, which acts by sequestering lymphocytes within lymph nodes.<\/jats:p>\n <\/jats:sec>\n \n Objective:<\/jats:title>\n To describe a case of extrapulmonary cryptococcosis in a patient taking fingolimod.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Case report.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n A 47-year-old man developed a non-healing skin lesion approximately 16\u2009months after starting treatment with fingolimod. Biopsy revealed cryptococcosis. Fingolimod was discontinued and the lesion resolved with antifungal therapy.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Despite few reported opportunistic infections in the pivotal clinical trials and first few years post-marketing, there has been a recent increase in reported AIDS-defining illnesses in patients taking fingolimod. Neurologists should be alert for opportunistic infections in their patients using this medication.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/1352458516670732","type":"journal-article","created":{"date-parts":[[2017,2,6]],"date-time":"2017-02-06T18:57:04Z","timestamp":1486407424000},"page":"297-299","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":25,"title":["Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?"],"prefix":"10.1177","volume":"23","author":[{"given":"Adam F","family":"Carpenter","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, USA\/Brain Sciences Center, VA Medical Center, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha J","family":"Goodwin","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, USA\/Brain Sciences Center, VA Medical Center, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F","family":"Bornstein","sequence":"additional","affiliation":[{"name":"St. Paul Infectious Disease Associates, Ltd., St. Paul, MN, USA\/Allina Health, St. Paul, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Larson","sequence":"additional","affiliation":[{"name":"Twin Cities Dermatopathology, Plymouth, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine K","family":"Markus","sequence":"additional","affiliation":[{"name":"St Croix Dermatology, Stillwater, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,2,6]]},"reference":[{"key":"bibr1-1352458516670732","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182143564"},{"key":"bibr2-1352458516670732","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000327609.57688.ea"},{"key":"bibr3-1352458516670732","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907839"},{"key":"bibr4-1352458516670732","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70049-3"},{"key":"bibr5-1352458516670732","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513500551"},{"key":"bibr6-1352458516670732","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001929"},{"key":"bibr7-1352458516670732","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.4259"},{"key":"bibr8-1352458516670732","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001556"},{"key":"bibr9-1352458516670732","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514555788"},{"key":"bibr10-1352458516670732","unstructured":"Novartis. Long-term efficacy of Gilenya\u00ae reinforced by new \u201cno evidence of disease activity\u201d (NEDA-4) analysis in MS patients over seven years, vol. 1. Novartis International, 2015, pp. 9\u201314, http:\/\/multimediacapsule.thomsonone.com\/novartis\/ectrims-neda-4-press-release-"},{"key":"bibr11-1352458516670732","doi-asserted-by":"publisher","DOI":"10.1086\/368091"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458516670732","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1352458516670732","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458516670732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:48:13Z","timestamp":1777693693000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458516670732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1177\/1352458516670732"],"URL":"https:\/\/doi.org\/10.1177\/1352458516670732","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}